Giant Industries, Inc. GI
8.00 0.00 (+0.00%)
At closeJun 28, 2019, 6:07 PM EDT
7.95 Day range 8.00
3.64 52-week range 9.47
- EPS (ttm)
- -3.59
- P/E ratio
- -2.23
- Volume
- 14.18K
- Avg volume
- 128.52K
- Open
- 8.00
- Previous close
- 8.00
- Day's range
- 7.95 – 8.00
- 52-week range
- 3.64 – 9.47
- Earnings date
- Nov 24, 2016
No chart data for this range yet.
Next earnings
Nov 24, 2016
Expected Nov 24, 2016. Consensus EPS estimate -0.52.
Financials — quick view
GI Revenue — quarterly 19.15M
GI Net income — quarterly -17.36M
GI EPS — quarterly -0.69
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 24, 2016 | Sep 1, 2016 | -0.52 | — | — | — |
| Aug 3, 2016 | Jun 1, 2016 | -0.52 | — | — | — |
| May 4, 2016 | Mar 1, 2016 | -0.54 | — | — | — |
| Mar 3, 2016 | Dec 1, 2015 | -0.60 | — | — | — |
| Nov 5, 2015 | Sep 1, 2015 | -0.54 | — | — | — |
| Aug 6, 2015 | Jun 1, 2015 | -0.90 | — | — | — |
News
Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01 
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S 
Sun Pharma Announces UNLOXCYT® (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patien 
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results 
Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers 
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types 
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide 
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026 
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC) 
Alight Adds Cylinder and Leap to Partner Network
Your note
Sign in to keep a note on GI — it syncs with the Stock Master app.